Reckitt CEO stands by Mead Johnson deal, despite Pfizer option

LONDON, March 10 (Reuters) - Reckitt Benckiser has no regrets about its $17 billion acquisition of Mead Johnson last year, its chief executive said, even though there are concerns it may now be too stretched to buy Pfizer's coveted consumer health business.